Efficacy and safety of tofacitinib in ankylosing spondylitis patients: a systematic review and meta-analysis.
Shen L · 2026 · Clinics (Sao Paulo, Brazil)
Reading the original? How to read a paper.
What this paper found
Pooling the randomised trials of tofacitinib (Xeljanz) in ankylosing spondylitis, people on the drug were about twice as likely to reach the standard response targets, with gains in function and quality of life, and overall side-effect rates matched placebo apart from more upper respiratory infections. It confirms tofacitinib as an effective oral option, with colds and sinus infections the main trade-off.
Why this is on the map
Trial-level summary for tofacitinib, which the JAK thread covered only through single studies.
On the map under this thread
DOI: 10.1016/j.clinsp.2026.101147 · opens in a new tab. The full paper is on the publisher’s site, not here.
Related papers on the board
Papers sharing one or more threads with this one.
Current status and emerging trends in biological therapies for ankylosing spondylitis: a bibliometric analysis (2004–2024)
Medicine (LWW)
Bibliometric analysis of biological therapies for AS over 2004-2024. Confirms three pillars, TNF, IL-17, and JAK inhibitors, and a persistent inadequate response in a meaningful subset of patients across all three classes.
Advances in Axial Spondyloarthritis Treatment: The Role of Janus Kinase Inhibitors
International Journal of Rheumatic Diseases
Reviews the JAK inhibitor class, tofacitinib, upadacitinib, filgotinib, for axial spondyloarthritis. The 2025 CRA/SPARCC guidelines still place TNF inhibitors first-line, with JAK inhibitors recommended when TNFi is contraindicated or for patients with comorbid IBD.
Recent advances in biologic therapies for ankylosing spondylitis: a 2024 update
Allergologia et Immunopathologia
Comprehensive bDMARD review covering TNF, IL-17, and JAK inhibitor classes with their efficacy and safety profiles across the AS treatment landscape. Confirms a meaningful patient subset still has inadequate response across all three drug classes.
Efficacy of JAK inhibitors in immune-mediated inflammatory diseases: 2024 update of an international consensus statement
Annals of the Rheumatic Diseases
Systematic literature review of JAK inhibitor efficacy across immune-mediated inflammatory diseases. Effective broadly, but isoform selectivity (JAK1/2/3/TYK2) and the data on tapering or withdrawal remain unclear.